Institute Curie

Saint-Cloud, France

Institute Curie

Saint-Cloud, France
SEARCH FILTERS
Time filter
Source Type

Patent
Institute Curie and Harmonic Pharma | Date: 2017-02-08

The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.


Patent
Polyquant GmbH, Biomedical Research Foundation Of The Academy Of Athens, Luxembourg Institute Of Health, Institute Curie, Assistance Publique Hopitaux De Paris and Diagnoswiss SA | Date: 2017-06-28

The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.


Patent
Institute Curie and French National Center for Scientific Research | Date: 2017-07-12

The present invention provides new peptides useful as skin whitening agents and their uses in cosmetic or therapeutic applications.


Patent
Abivax, French National Center for Scientific Research, Institute Curie and Montpellier University | Date: 2017-04-13

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where:


Patent
French National Center for Scientific Research and Institute Curie | Date: 2017-01-25

A minifluidic device comprising a matrix, an elongated guiding duct 109 embedded at least in part in said matrix, with at least one port to the outside of the matrix, a movable fiber 104 at least partly contained in said guiding duct 109, and able to undergo within said guiding duct 109, and at least along some part of said fiber 104, at least one action selected among a sliding, or a deformation, or a rotation, at least one zone in fluidic connection with said guiding duct 109, said zone being selected from: a fluid drop area, a reservoir, or a chamber 107.


Patent
French National Center for Scientific Research and Institute Curie | Date: 2017-01-25

A fluidic device comprising at least:a/ a solid matrix 5,b/ a textile component 4, embedded in said matrix and mechanically cohesive with said matrix,c/ at least one channel 6 embedded in said matrix and entangled with said textile component 4, said channel 6 being at least partly open. A method for making a fluidic device comprising providing a textile component 4 comprising support fibers 1.1, 1.2 and at least a movable fiber 2 entangled with said textile 4, embedding at least part of said textile 4 and part of said movable fiber 2, in a matrix precursor material 5, applying a treatment in order to obtain a solid matrix 5.


Patent
Dna Therapeutics, Institute Curie and French National Center for Scientific Research | Date: 2017-03-01

The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.


Patent
Institute Curie | Date: 2017-03-01

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-IL2 response, peptides specifically recognised by anti-IL2 antibodies or IL-2-specific T cells of T1D, systemic lupus erythematosus, rheumatoid arthritis, Sjgrens syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.


Patent
Theravectys, Institute Curie and French National Center for Scientific Research | Date: 2017-05-31

The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.


Patent
Abivax, French National Center for Scientific Research and Institute Curie | Date: 2017-05-24

The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable excipient, to a process for preparing said compound and to a corresponding intermediate compound.

Loading Institute Curie collaborators
Loading Institute Curie collaborators